At the time of this report, the two patients were both alive and had a very good skin response. This report shows that imatinib is effective in patients with refractory sclerodermatous cGVHD.

The clinical assessment of the symptoms and signs of cGVHD was based on the NIH consensus development project on ... The median time from transplant to commencing ECP was 1.7 years (3 months ...

Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), particularly in specific cases where other therapies may not be effective.